News archive.
Earlier AI news and analysis, kept for reference. Current coverage lives in News & Analysis.
Healthcare AI market forecast to hit $505.6B by 2033
Market researchers project healthcare AI spending will grow to $505.6 billion by 2033, citing adoption of clinical AI tools and digital healthcare expansion. What's driving the forecast and where practitioners should focus.
IBM Claims First Sub-1 Nanometer Chip—What It Actually Means
IBM announced a sub-1 nanometer chip technology. The claim uses a new measurement method. What this means for production timelines and competing foundries remains unclear.
Merck to acquire Bio-Techne for life sciences expansion
Merck KGaA announced plans to acquire Bio-Techne, a move aimed at strengthening its position in fast-growing life sciences markets. Details on deal value and timing remain limited.
Deloitte Adds Agentic AI to Omnia Audit Platform
Deloitte embedded connected agentic intelligence into Omnia, its audit and assurance software. The move signals how Big Four firms are integrating AI agents into core workflows.
Assort Health Closes $120M Series C for AI Agent Deployment in Healthcare
Assort Health raised $120 million in Series C funding to scale what it claims is the largest deployment of AI agents across the patient journey. The round signals investor confidence in clinical automation, but independent verification of scale claims remains unavailable.
NICE backs pembrolizumab for cervical cancer with chemo-radiation
England's health authority approves MSD's immunotherapy as first-line treatment for locally advanced cervical cancer, based on phase 3 trial data showing improved survival.
Racura Treats First Lung Cancer Patient on RC220 Plus Osimertinib
Racura Oncology dosed the first patient in HARNESS-1, a phase 1 trial combining RC220 with standard-of-care osimertinib for EGFR-mutant lung cancer. No adverse events reported at the 50mg/m² starting dose.
Novartis bets $1.9B on Antares to crack undruggable cancer targets
Novartis will pay up to $1.9 billion to collaborate with biotech Antares Therapeutics on small-molecule oncology drugs. Antares' lead program enters clinical trials in 2026.
NIH funding cuts leave US biotech vulnerable to China's push
Investors at BIO 2026 warn that federal research funding declines risk America's leadership in drug development as Chinese competitors scale globally.
RQ Bio Raises $115M for Influenza Antibody in Immunocompromised
RQ Bio closed a Series A to develop RQB01, a long-acting antibody designed to protect high-risk and immunocompromised patients against influenza. The lead asset is in IND-enabling studies.
Lilly's $21B Indiana bet reshapes state biotech competition
Since 2020, Eli Lilly invested $21B in Indiana, including $4.5B announced last month. The company's GLP-1 boom is now funding suppliers, workforce training, and the state's bid to compete with California, Massachusetts for biopharma talent.
MSD's bladder cancer combo hits EU approval with 60% survival edge
European Commission approves Keytruda plus Padcev for muscle-invasive bladder cancer. The combination cut event-free survival risk by 60% in Phase III trials.